In this article, we will discuss 7 Best Longevity and Anti-Aging Stocks to Buy.
The next frontier of human health may not be found in a hospital; it may be unlocked in a laboratory. That’s the audacious premise behind longevity and anti-aging stocks, a sector drawing serious capital from billionaire investors, sovereign wealth funds, and life sciences-focused institutions positioning ahead of what could be the most consequential medical breakthrough cycle of the century. And unlike oncology or GLP-1s, this is not yet a crowded trade. It’s an emerging scientific frontier where the upside is potentially generational, but only for those who can separate genuine biological innovation from headline noise.
The investment case is being driven by demographics and data in equal measure. An aging global population, rising chronic disease burden, and the compounding cost of late-stage healthcare are creating immense structural pressure on traditional medicine to shift from treatment to prevention. Longevity science, spanning senolytics, epigenetic reprogramming, NAD+ metabolism, and mTOR pathway intervention, offers a fundamentally different proposition: extending health span, not just lifespan. Data from Grand View Research projects the global anti-aging market to grow from approximately $72 billion in 2024 at a CAGR of between 7% to 9% through 2032, driven by rising consumer spending on longevity therapeutics, diagnostics, and preventive biologics.
At the same time, academic research from institutions including the Buck Institute, Harvard Medical School, and platforms like bioRxiv is validating the biological mechanisms underlying aging reversal at a pace that would have seemed implausible a decade ago. Breakthroughs in partial reprogramming and epigenetic clock reversal are moving from peer-reviewed theory into early-stage clinical pipelines, reinforcing the long-term scientific credibility of the sector and signaling that longevity medicine is transitioning from fringe to mainstream.
Longevity science has necessity and desire; a global population that is simultaneously living longer and demanding to live better. For funds hunting asymmetric opportunities at the intersection of biology, technology, and an inevitable demographic tide, longevity and anti-aging stocks may be one of the most intellectually compelling and structurally undervalued themes in the market today.
With this context in mind, here are some longevity and anti-aging stocks to buy.
Our Methodology
We used stock screeners to identify longevity and anti-aging stocks with a short percentage of shares outstanding, less than 3%. We limited our final selection to companies that have recently reported noteworthy developments likely to impact investor sentiment. These stocks are also popular among analysts and elite hedge funds. To make the list easier to navigate, we ranked the stocks in descending order of their short percentage of shares outstanding as of May 29, 2026.
“Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Insider Monkey’s quarterly newsletter strategy selects 14 small-cap and large-cap stocks every quarter and has returned 599.2% since May 2014, beating its benchmark by 372 percentage points (see more details here).”
7 Best Longevity and Anti-Aging Stocks to Buy
7. UnitedHealth Group Incorporated (NYSE:UNH)
Short Percentage of Shares Outstanding: 2.12%
On June 12, subsidiaries of UnitedHealth Group Incorporated (NYSE:UNH), including OptumRx and Emisar Pharma Services, reached an agreement with the Federal Trade Commission to settle allegations that the companies engaged in anticompetitive and unfair rebating practices related to insulin drug pricing. Under the agreement, the matter will be withdrawn from adjudication with respect to the Optum entities while the Commission evaluates a proposed consent agreement intended to fully resolve the claims against them. The Federal Trade Commission ordered that all proceedings involving the Optum respondents be stayed pending the Commission’s review and determination regarding the proposed settlement, representing a significant step toward resolving the regulatory matter.
On June 8, JPMorgan raised its price target on UnitedHealth Group to $466 from $420 while maintaining an Overweight rating on the shares. The firm updated its healthcare services models and increased its valuation outlook, reflecting continued confidence in the company’s long-term earnings potential and market position within the healthcare sector.
Founded in 1974 and headquartered in Minnetonka, Minnesota, UnitedHealth Group operates through UnitedHealthcare for delivering health insurance and Optum for providing pharmacy benefits and care services. It funds healthy aging research through the United Health Foundation and expands Medicare Advantage to support longevity outcomes.
6. Gilead Sciences, Inc. (NASDAQ:GILD)
Short Percentage of Shares Outstanding: 2.07%
On June 15, Gilead Sciences, Inc. (NASDAQ:GILD) announced that the U.S. Food and Drug Administration accepted its supplemental New Drug Application for Yeztugo 300-mg tablets as a potential once-weekly oral pre-exposure prophylaxis (PrEP) treatment for HIV prevention. The Food and Drug Administration assigned a Prescription Drug User Fee Act (PDUFA) target action date of February 2, 2027, marking an important regulatory milestone for the program. If approved, the therapy could expand Gilead’s HIV prevention portfolio by offering patients a convenient once-weekly oral dosing option.
On June 12, Gilead Sciences, Inc. (NASDAQ:GILD) announced the donation of more than 2,000 vials of its intravenous antiviral therapy remdesivir to the Republic of Uganda to support efforts to combat the ongoing Ebola Bundibugyo virus outbreak. The company stated that the donation reflects its commitment to responding rapidly to global health emergencies and leveraging its extensive experience in infectious disease management. Management emphasized that Gilead is working closely with partners and health authorities to help address the outbreak and support affected communities.
Founded in 1987 and headquartered in Foster City, California, Gilead Sciences, Inc. (NASDAQ:GILD) is a biopharmaceutical company that discovers, develops, and commercializes innovative therapeutics for life-threatening diseases, particularly in virology, oncology, and inflammation. It transforms fatal & chronic conditions (like HIV and Hepatitis C) into highly manageable, long-term states of health.
While we acknowledge the potential of GILD as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than GILD and that has 100x upside potential, check out our report about the cheapest AI stock.
Click to continue reading and see the 5 Best Longevity and Anti-Aging Stocks to Buy.
Disclosure: None. Follow Insider Monkey on Google News.
